---
document_datetime: 2023-09-21 19:17:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/evra-epar-all-authorised-presentations_en.pdf
document_name: evra-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7859618
conversion_datetime: 2025-12-19 07:07:12.471659
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical Form   | Route of        | Packaging   | Package size           |
|-----------------|-----------------|------------|-----------------------|-----------------|-------------|------------------------|
| EU/1/02/223/001 | EVRA            | - 1 -      | Transdermal patch     | Transdermal use | sachet      | 3 transdermal patches  |
| EU/1/02/223/002 | EVRA            | - 1 -      | Transdermal patch     | Transdermal use | sachet      | 9 transdermal patches  |
| EU/1/02/223/003 | EVRA            | - 1 -      | Transdermal patch     | Transdermal use | sachet      | 18 transdermal patches |

1 Each transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE). Each transdermal patch releases 203 micrograms of NGMN and 33.9 micrograms of EE per 24 h.